Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_02207 |
| Species: | Homo sapiens |
| Position : | chr21:40149729-40317726 |
| Year: | 2023 |
| Title: | A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer. |
| Genome Build: | hg38 |
| Enhancer Type: | Super-enhancer |
| Condition: | Disease |
| Disease Name: | colorectal carcinoma |
| PMID: | 36609474 |
| MONDO: | MONDO:0024331 |
| Tissue: | colon |
| Tissue Ontology ID: | UBERON:0001155 |
| Cell Source: | HCT 116 |
| CVCL ID: | CVCL_0291 |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Super-enhancer activity; TF binding; chromatin interaction; CRISPRi functional perturbation |
| High Throughput Method: | H3K27ac ChIP-seq; RNA-seq; promoter capture Hi-C; MECOM ChIP-seq; 5' CAGE |
| Low Throughput Method: | dCas9-KRAB CRISPRi; 3CqPCR; CUT&Tag-qPCR; RT-qPCR; Western blot |
| Target gene : | ETS2 |
| TF name : | MECOM |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MECOM | PKMTs methylate histone lysines | reactome | 64 |
| MECOM | MAPK signaling pathway | kegg | 264 |
| MECOM | Pathways in cancer | kegg | 321 |
| MECOM | Chronic myeloid leukemia | kegg | 69 |
| MECOM | Hs_White_fat_cell_differentiation_WP3946_90940 | wikipathways | 30 |